TEVA PHARMACEUTICAL

Teva and Medincell’s new joint venture on olanzapine LAI promises $30 M revenue and cost savings, but must overcome regulatory, competitive, and debt‑risk hurdles.

Teva teams up with Polpharma to launch a cost‑effective ocrelizumab biosimilar for MS, leveraging SC dosing and global sales to tap a $17.5 B market and secure early market share.

Teva’s new Ocrevus biosimilar license unlocks a $250‑$350 million MS market, blending low‑cost development, global reach and strategic growth in high‑barrier therapy.

Teva’s partnership with Medincell advances BEPO® long‑acting injectables, securing FDA/EMA approvals, expanding U.S., Canada and South Korean markets, and boosting psychiatric therapeutic reach.